Literature DB >> 25531317

Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway.

M K Siu1,2, Y-C Tsai1,3, Y-S Chang3, J J Yin4, F Suau4, W-Y Chen5, Y-N Liu1,3.   

Abstract

Transforming growth factor-β (TGFβ) is enriched in the bone matrix and serves as a key factor in promoting bone metastasis in cancer. In addition, TGFβ signaling activates mammalian target of rapamycin (mTOR) functions, which is important for the malignant progression. Here, we demonstrate that TGFβ regulates the level of microRNA-96 (miR-96) through Smad-dependent transcription and that miR-96 promotes the bone metastasis in prostate cancer. The enhanced effects in cellular growth and invasiveness suggest that miR-96 functions as an oncomir/and metastamir. Supporting this idea, we identified a downstream target of the TGFβ-miR-96 signaling pathway to be AKT1S1 mRNA, whose translated protein is a negative regulator of mTOR kinase. Our findings provide a novel mechanism accounting for the TGFβ signaling and bone metastasis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25531317     DOI: 10.1038/onc.2014.414

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition.

Authors:  Philip Martin; Yen-Nien Liu; Rachel Pierce; Wassim Abou-Kheir; Orla Casey; Victoria Seng; Daniel Camacho; R Mark Simpson; Kathleen Kelly
Journal:  Am J Pathol       Date:  2011-05-13       Impact factor: 4.307

2.  Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells.

Authors:  Mingfang Ao; Karin Williams; Neil A Bhowmick; Simon W Hayward
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 4.  TGFbeta signalling: a complex web in cancer progression.

Authors:  Hiroaki Ikushima; Kohei Miyazono
Journal:  Nat Rev Cancer       Date:  2010-06       Impact factor: 60.716

5.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.

Authors:  Pradip K Majumder; Phillip G Febbo; Rachel Bikoff; Raanan Berger; Qi Xue; Louis M McMahon; Judith Manola; James Brugarolas; Timothy J McDonnell; Todd R Golub; Massimo Loda; Heidi A Lane; William R Sellers
Journal:  Nat Med       Date:  2004-05-23       Impact factor: 53.440

6.  Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.

Authors:  X Li; V Placencio; J M Iturregui; C Uwamariya; A-R Sharif-Afshar; T Koyama; S W Hayward; N A Bhowmick
Journal:  Oncogene       Date:  2008-08-25       Impact factor: 9.867

7.  Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1.

Authors:  Benedikta S Haflidadóttir; Olivia Larne; Myriam Martin; Margareta Persson; Anders Edsjö; Anders Bjartell; Yvonne Ceder
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

8.  Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53.

Authors:  Vikas Yadav; Sarwat Sultana; Jyoti Yadav; Neeru Saini
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

9.  Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway.

Authors:  Samy Lamouille; Rik Derynck
Journal:  J Cell Biol       Date:  2007-07-23       Impact factor: 10.539

10.  The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1.

Authors:  Annika Fendler; Monika Jung; Carsten Stephan; Andreas Erbersdobler; Klaus Jung; George M Yousef
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240

View more
  45 in total

Review 1.  MicroRNAs in prostate cancer: From function to biomarker discovery.

Authors:  Ahmed A Moustafa; Hogyoung Kim; Rasha S Albeltagy; Ola H El-Habit; Asim B Abdel-Mageed
Journal:  Exp Biol Med (Maywood)       Date:  2018-06

Review 2.  The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs.

Authors:  Ulrich H Weidle; Alexandra Epp; Fabian Birzele; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2019 Jan-Feb       Impact factor: 4.069

3.  EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1.

Authors:  Yung-Sheng Chang; Wei-Yu Chen; Juan Juan Yin; Heather Sheppard-Tillman; Jiaoti Huang; Yen-Nien Liu
Journal:  Cancer Res       Date:  2015-06-12       Impact factor: 12.701

4.  SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival.

Authors:  J Y Liu; Q H Zeng; P G Cao; D Xie; F Yang; L Y He; Y B Dai; J J Li; X M Liu; H L Zeng; X J Fan; L Liu; Y X Zhu; L Gong; Y Cheng; J D Zhou; J Hu; H Bo; Z Z Xu; K Cao
Journal:  Oncogene       Date:  2018-04-17       Impact factor: 9.867

5.  Cell-autonomous and cell non-autonomous downregulation of tumor suppressor DAB2IP by microRNA-149-3p promotes aggressiveness of cancer cells.

Authors:  Arianna Bellazzo; Giulio Di Minin; Elena Valentino; Daria Sicari; Denis Torre; Luigi Marchionni; Federica Serpi; Michael B Stadler; Daniela Taverna; Gaia Zuccolotto; Isabella Monia Montagner; Antonio Rosato; Federica Tonon; Cristina Zennaro; Chiara Agostinis; Roberta Bulla; Miguel Mano; Giannino Del Sal; Licio Collavin
Journal:  Cell Death Differ       Date:  2018-03-22       Impact factor: 15.828

6.  TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.

Authors:  M K Siu; W-Y Chen; H-Y Tsai; H-Y Chen; J J Yin; C-L Chen; Y-C Tsai; Y-N Liu
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-02-21       Impact factor: 5.554

Review 7.  Emerging Role of MicroRNAs in mTOR Signaling.

Authors:  Yanjie Zhang; Bo Huang; Hui-Yun Wang; Augustus Chang; X F Steven Zheng
Journal:  Cell Mol Life Sci       Date:  2017-02-25       Impact factor: 9.261

Review 8.  MicroRNA Exert Macro Effects on Cancer Bone Metastasis.

Authors:  Scott R Baier; Yihong Wan
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 9.  Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches.

Authors:  Valentina Doldi; Marzia Pennati; Barbara Forte; Paolo Gandellini; Nadia Zaffaroni
Journal:  Cell Mol Life Sci       Date:  2016-03-12       Impact factor: 9.261

Review 10.  Molecular mechanisms and clinical management of cancer bone metastasis.

Authors:  Manni Wang; Fan Xia; Yuquan Wei; Xiawei Wei
Journal:  Bone Res       Date:  2020-07-29       Impact factor: 13.567

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.